Extended interval dosing of natalizumab: More evidence in support

被引：1
|
作者：
Toljan, Karlo [1 ]
Conway, Devon S. [1 ]
机构：
[1] Cleveland Clin, Neurol Inst, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave U10, Cleveland, OH 44195 USA
来源：
NEUROTHERAPEUTICS | 2024年 / 21卷 / 03期
关键词：
Multiple sclerosis; Disease-modifying therapy; Natalizumab; Extended interval dosing;
D O I：
10.1016/j.neurot.2024.e00351
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients
    Petrzalka, M.
    Meluzinova, E.
    Mojzisova, H.
    Libertinova, J.
    Rockova, P.
    Nema, E.
    Elisak, M.
    Marusic, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (01) : 79 - 83
  • [22] Extended interval dosing and reduced dose of natalizumab in a Portuguese population
    Marques, P.
    Correia, I.
    Batista, S.
    Nunes, C.
    Macario, C.
    Campelo, I.
    Sousa, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 782 - 783
  • [23] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
    van Kempen, Zoe L. E.
    Hoogervorst, Erwin L. J.
    Wattjes, Mike P.
    Kalkers, Nynke F.
    Mostert, Jop P.
    Lissenberg-Witte, Birgit I.
    de Vries, Annick
    ten Brinke, Anja
    van Oosten, Bob W.
    Barkhof, Frederik
    Teunissen, Charlotte E.
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    NEUROLOGY, 2020, 95 (06) : E745 - E754
  • [24] Natalizumab extended-interval dosing in a real-life setting
    Jeantin, Lina
    de la Motte, Marine Boudot
    Deschamps, Romain
    Gueguen, Antoine
    Gout, Olivier
    Lecler, Augustin
    Papeix, Caroline
    Bensa, Caroline
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 450
  • [25] Effectiveness and safety profile of the natalizumab extended interval dosing in a spanish cohort
    Costa-Frossard, L.
    Sainz De La Maza, S.
    Monreal, E.
    Gomez Lopez, A.
    Fernandez-Velasco, J. I.
    Walo Delgado, P.
    Espino, M.
    Villarrubia, N.
    Masjuan, J.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 278 - 278
  • [26] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS
    Ryerson, Lana Zhovtis
    Naismith, Robert T.
    Krupp, Lauren B.
    Charvet, Leigh
    Liao, Shirley
    Fisher, Elizabeth
    De Moor, Carl
    Williams, James R.
    Licata, Stephanie
    Campbell, Nolan
    NEUROLOGY, 2021, 96 (15)
  • [27] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths
    Zhovtis-Ryerson, L.
    Naismith, R. T.
    Krupp, L.
    Charvet, L.
    Su, R.
    Fisher, E.
    De Moor, C.
    Williams, J.
    Campbell, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 293 - 293
  • [28] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
    Ryerson, Lana Zhovtis
    Foley, John
    Kister, Ilya
    Frohman, Teresa
    Pandey, Krupa
    Lu, Xiaochun
    Goldberg, Judith
    Zuniga-Estrada, Guadalupe
    Hoyt, Tammy
    Jacob, April
    Bacon, Tamar
    Major, Eugene
    Frohman, Elliot
    NEUROLOGY, 2017, 88
  • [29] Extended dosing interval reduces risk of natalizumab-related PML
    Reactions Weekly, 2019, 1772 (1) : 9 - 9
  • [30] Mri activity and extended interval of natalizumab dosing: a multicenter italian study
    Clerico, M.
    De Mercanti, S. F.
    Signori, A.
    Iudicello, M.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Bonavita, S.
    Lavorgna, L.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Mataluni, G.
    Landi, D.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 538 - 538
12345